港股異動 | 百濟神州(6160.HK)高開近15% 百悦澤在無進展生存期終期分析中取得積極結果
格隆匯10月13日丨百濟神州(6160.HK)高開14.97%,報88.3港元,總市值1190億港元。該公司昨日公吿,在全球3期ALPINE試驗的一項終期分析中,經獨立評審委員會(IRC)及研究者評估,自主研發產品BTK抑制劑百悦澤(澤布替尼)對比億珂(伊布替尼),取得無進展生存期(PFS)的優效性結果。澤布替尼總體耐受性良好,本次分析顯示的安全性結果與既往報吿中一致。百濟神州血液學首席醫學官Mehrdad Mobasher醫學博士及公共衞生碩士表示:“這一積極結果進一步充實了我們的臨牀證據,驗證了澤布替尼有潛力為慢性淋巴細胞白血病(CLL)這一難治疾病的患者帶來新的希望。這項PFS終期分析顯示,澤布替尼在無進展生存期和總緩解率方面相較伊布替尼具有優效性。我們期待與醫療專業人士和患者分享詳盡的研究結果,並計劃在醫學大會進行公佈以及在專業文獻上發表”。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.